Australia Reschedules Psilocybin and MDMA to Begin Treating TRD and PTSD
Policy
Good news from the Australian Therapeutic Goods Administration, as they will now allow for the prescription of MDMA to treat post-traumatic stress disorder (PTSD), and psilocybin to combat treatment-resistant depression. This new classification is a step forward in providing relief with alternative treatments that have been proven effective.
I am already really worried that our ability to study and use psychedelics will be repressed before their benefits can reach the millions who want/need them. Part of the problem is that media and those with legal access to MDMA and ketamine for use in clinical settings are touting them as psychedelics. These are not pure psychedelics. The proliferation of treatment centres offering MDMA and K as psychedelics increases the odds of these treatments getting negative public attention like this, which puts actual psychedelic research (using psilocybin/LSD) at risk. I have just written a blog post about my concerns. https://iamallwrite.com/2022/07/16/psychedelics-pose-threats-to-powerful-groups-with-vested-interests-we-need-to-support-initiatives-to-make-them-available-for-therapeutic-use/